{"id":"W2944167983","doi":"10.1093/annonc/mdz128","title":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma; Novartis; Genentech; Merck","keywords":"Erlotinib; Gefitinib; Medicine; Tolerability; T790M; Internal medicine; Lung cancer; Hazard ratio; Erlotinib Hydrochloride; Oncology; Epidermal growth factor receptor; Cancer; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001903801,0.002228814,0.003712842,0.0004528576,0.0006079192,0.001513817,0.001070244,0.001900738,0.007379963],"category_scores_gemma":[0.001518492,0.0009258554,0.002298643,0.0005417789,0.001668356,0.001902569,0.0004472779,0.005077146,0.001633937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001224678,"about_ca_system_score_gemma":0.001579114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001460378,"about_ca_topic_score_gemma":0.004069419,"domain_scores_codex":[0.9993398,0.0003331967,0.0000308314,0.0001192056,0.00004201132,0.0001349454],"domain_scores_gemma":[0.9990212,0.0002754836,0.0001727076,0.00008046705,0.00006329511,0.0003869423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9728526,0.0108751,0.0005678794,0.0003009469,0.0007464373,0.00003558996,0.00005208485,0.0005676008,0.001974263,0.0001057242,0.0009223118,0.01099952],"study_design_scores_gemma":[0.9420878,0.05542319,0.001015013,0.00001137737,0.0002479719,0.00002563461,0.00002936033,0.0004097332,0.0001884778,0.0001266805,0.0004220417,0.00001273792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874356,0.002806873,0.000729497,0.001013897,0.0007363426,0.003107189,0.001368453,0.0001387499,0.002663449],"genre_scores_gemma":[0.9861085,0.00208118,0.001471327,0.00153297,0.0004579966,0.003086945,0.001536065,0.00004679016,0.003678241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007379963,"threshold_uncertainty_score":0.02468836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0629895344694283,"score_gpt":0.4538235096787264,"score_spread":0.3908339752092981,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}